(II) 复合体对粉样蛋白聚合的抑制作用:一种理论和实验方法
Sara La Manna1, Valentina Roviello2, Vittoria Monaco3,4
1Department of Pharmacy, University of Naples Federico II, 80131, Naples, Italy. daniela.marasco@unina.it.
Dalton transactions (Cambridge, England : 2003)
|September 1, 2023
概括
(II) 复合物,如甲,通过在与神经退行性疾病相关的模型中有效抑制粉样蛋白聚合,显示出作为神经治疗药物的潜力.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 生物物理学的生物物理.
背景情况:
- (II) 方形平面复合物是已确立的抗癌药物,其作用机制由连接物特性调节.
- 像Sup35p7-13和NPM1264-277这样的类胺基蛋白自我聚合与神经退行性疾病有关.
研究的目的:
- 调查四个Pt(II) 复合体在调节氨基原自我聚合中的潜力.
- 通过重新利用金属药物来识别新的神经治疗药物.
主要方法:
- 生物物理分析包括提奥夫拉T (ThT) 光,电喷射电离化质谱法 (ESI-MS) 和紫外线吸收光谱法.
- 分子动态模拟以阐明相互作用机制.
主要成果:
- 甲在抑制粉样蛋白聚合和分解可溶性聚合物方面表现出显著的有效性.
- 观察到三丁与粉样结构的直接协调,涉及连接体损失和π-π和π-相互作用的形成.
结论:
- 南是一种强大的粉样蛋白聚合调节剂,表明其作为神经治疗剂的潜力.
- 金属药物再利用是开发神经退行性疾病新疗法的一个有希望的策略.
相关概念视频
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
EDTA: Auxiliary Complexing Reagents
616
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
616


